AU2012345645B2 - Immunogenic composition comprising panton-valentine leukocidin (PVL) derived polypeptides - Google Patents

Immunogenic composition comprising panton-valentine leukocidin (PVL) derived polypeptides Download PDF

Info

Publication number
AU2012345645B2
AU2012345645B2 AU2012345645A AU2012345645A AU2012345645B2 AU 2012345645 B2 AU2012345645 B2 AU 2012345645B2 AU 2012345645 A AU2012345645 A AU 2012345645A AU 2012345645 A AU2012345645 A AU 2012345645A AU 2012345645 B2 AU2012345645 B2 AU 2012345645B2
Authority
AU
Australia
Prior art keywords
mutant
luks
seq
subunit
leukocidin subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012345645A
Other languages
English (en)
Other versions
AU2012345645A1 (en
Inventor
Rajan Prasad ADHIKARI
Mohammad Javad Aman
Hatice KARAUZUM
Tam Luong NGUYEN
Jawad Sarwar
Sergey Shulenin
Sathya VENKATARAMANI
Kelly Lyn Warfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abvacc Inc
Original Assignee
Abvacc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abvacc Inc filed Critical Abvacc Inc
Publication of AU2012345645A1 publication Critical patent/AU2012345645A1/en
Application granted granted Critical
Publication of AU2012345645B2 publication Critical patent/AU2012345645B2/en
Assigned to INTEGRATED BIOTHERAPEUTIC VACCINES, INC. reassignment INTEGRATED BIOTHERAPEUTIC VACCINES, INC. Request for Assignment Assignors: INTEGRATED BIOTHERAPEUTICS, INC.
Assigned to ABVACC, INC. reassignment ABVACC, INC. Request to Amend Deed and Register Assignors: INTEGRATED BIOTHERAPEUTIC VACCINES, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012345645A 2011-12-02 2012-11-30 Immunogenic composition comprising panton-valentine leukocidin (PVL) derived polypeptides Active AU2012345645B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161566234P 2011-12-02 2011-12-02
US61/566,234 2011-12-02
PCT/US2012/067483 WO2013082558A1 (en) 2011-12-02 2012-11-30 Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides

Publications (2)

Publication Number Publication Date
AU2012345645A1 AU2012345645A1 (en) 2014-06-26
AU2012345645B2 true AU2012345645B2 (en) 2017-09-07

Family

ID=48536149

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012345645A Active AU2012345645B2 (en) 2011-12-02 2012-11-30 Immunogenic composition comprising panton-valentine leukocidin (PVL) derived polypeptides

Country Status (13)

Country Link
US (1) US10023848B2 (enExample)
EP (1) EP2785368B1 (enExample)
JP (1) JP6325452B2 (enExample)
KR (1) KR101999299B1 (enExample)
AU (1) AU2012345645B2 (enExample)
CA (1) CA2857666C (enExample)
DK (1) DK2785368T3 (enExample)
ES (1) ES2728445T3 (enExample)
HR (1) HRP20190907T1 (enExample)
LT (1) LT2785368T (enExample)
RS (1) RS58919B1 (enExample)
SI (1) SI2785368T1 (enExample)
WO (1) WO2013082558A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857666C (en) 2011-12-02 2020-08-11 Integrated Biotherapeutics, Inc. Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
CN110420316A (zh) 2013-06-18 2019-11-08 纽约大学 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点
CA2916231C (en) * 2013-06-19 2024-02-06 Integrated Biotherapeutics, Inc. Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CN105873946A (zh) * 2013-10-17 2016-08-17 阿尔萨尼斯生物科学有限责任公司 交叉反应性金黄色葡萄球菌抗体序列
JP6620817B2 (ja) * 2015-08-10 2019-12-18 株式会社微生物化学研究所 黄色ブドウ球菌不活化菌体とロイコシジンを混合したワクチン
CN107224575B (zh) * 2017-03-06 2018-11-09 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用
MX2020001046A (es) 2017-07-27 2020-08-06 Integrated Biotherapeutic Vaccines Inc Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos.
WO2025085539A1 (en) * 2023-10-16 2025-04-24 The Trustees Of Columbia University In The City Of New York Engineered bacteria for cellular barrier maintenance and protection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074755A1 (en) * 2005-06-13 2009-03-19 Nabi Biopharmaceuticals Use of panton-valentine leukocidin for treating and preventing staphylococcus infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20100158871A1 (en) 1999-08-30 2010-06-24 David Stephen Terman Sickled erythrocytes with antitumor molecules induce tumoricidal effects
US20050008633A1 (en) 2003-05-19 2005-01-13 Advanced Inhalation Research Inc. Chemical and physical modulators of bioavailability of inhaled compositions
US7754225B2 (en) 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection
EP2388593A3 (fr) * 2006-10-18 2012-01-18 bioMérieux Procédé de diagnostic in vitro des Staphylococcus aureus producteurs de PVL
CA2857666C (en) 2011-12-02 2020-08-11 Integrated Biotherapeutics, Inc. Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074755A1 (en) * 2005-06-13 2009-03-19 Nabi Biopharmaceuticals Use of panton-valentine leukocidin for treating and preventing staphylococcus infections

Also Published As

Publication number Publication date
EP2785368A1 (en) 2014-10-08
EP2785368A4 (en) 2015-12-30
LT2785368T (lt) 2019-06-10
NZ626762A (en) 2016-07-29
EP2785368B1 (en) 2019-03-13
SI2785368T1 (sl) 2019-08-30
WO2013082558A1 (en) 2013-06-06
AU2012345645A1 (en) 2014-06-26
JP6325452B2 (ja) 2018-05-16
HRP20190907T1 (hr) 2019-07-12
DK2785368T3 (da) 2019-05-27
ES2728445T3 (es) 2019-10-24
CA2857666C (en) 2020-08-11
US10023848B2 (en) 2018-07-17
US20140308291A1 (en) 2014-10-16
JP2015505831A (ja) 2015-02-26
KR20140117381A (ko) 2014-10-07
RS58919B1 (sr) 2019-08-30
KR101999299B1 (ko) 2019-07-12
CA2857666A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
EP2785368B1 (en) Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
AU2012214677B2 (en) Immunogenic composition comprising alpha-hemolysin oligopeptides
US10174085B2 (en) Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
US11421021B2 (en) Immunogenic compositions comprising Staphylococcus aureus leukocidin LukA and LukB derived polypeptides
JP2024540918A (ja) リポ多糖（ｌｐｓ）欠損アシネトバクター・バウマニ多価ワクチン
US11826412B2 (en) Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
US20180141981A1 (en) Immunogenic composition comprising engineered alpha-hemolysin oligopeptides
CA3066450C (en) Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides
NZ626762B2 (en) Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
GR1010289B (el) Τοξοειδη πεπτιδια που προερχονται απο διαλυτη σε φαινολη μοδουλινη, τοξινη δελτα, υπεραντιγονα και συντηξεις αυτων

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: INTEGRATED BIOTHERAPEUTIC VACCINES, INC.

Free format text: FORMER OWNER(S): INTEGRATED BIOTHERAPEUTICS, INC.

HB Alteration of name in register

Owner name: ABVACC, INC.

Free format text: FORMER NAME(S): INTEGRATED BIOTHERAPEUTIC VACCINES, INC.